Analysts expect that Denali Therapeutics Inc (NASDAQ:DNLI) will announce sales of $18.69 million for the current quarter, Zacks reports. Four analysts have provided estimates for Denali Therapeutics’ earnings, with estimates ranging from $4.50 million to $51.89 million. Denali Therapeutics reported sales of $125.68 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 85.1%. The company is scheduled to report its next earnings report on Tuesday, March 10th.
According to Zacks, analysts expect that Denali Therapeutics will report full-year sales of $43.94 million for the current fiscal year, with estimates ranging from $26.51 million to $83.79 million. For the next year, analysts anticipate that the firm will post sales of $66.51 million, with estimates ranging from $16.61 million to $175.00 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Denali Therapeutics.
Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.08. Denali Therapeutics had a negative return on equity of 13.37% and a negative net margin of 44.73%. The business had revenue of $13.60 million for the quarter, compared to the consensus estimate of $10.86 million.
A number of research firms recently issued reports on DNLI. BTIG Research began coverage on Denali Therapeutics in a report on Friday, August 9th. They issued a “buy” rating and a $30.00 target price for the company. Morgan Stanley set a $32.00 target price on Denali Therapeutics and gave the company a “buy” rating in a report on Friday, August 9th. Zacks Investment Research lowered Denali Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 7th. ValuEngine upgraded Denali Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Finally, Wedbush began coverage on Denali Therapeutics in a report on Wednesday, September 25th. They issued a “neutral” rating and a $19.00 target price for the company. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. Denali Therapeutics presently has an average rating of “Buy” and an average price target of $27.43.
DNLI stock traded up $0.11 during midday trading on Monday, hitting $15.25. 251,800 shares of the company’s stock were exchanged, compared to its average volume of 350,245. Denali Therapeutics has a 1-year low of $14.24 and a 1-year high of $28.86. The company has a current ratio of 10.59, a quick ratio of 10.59 and a debt-to-equity ratio of 0.16. The business has a 50-day simple moving average of $15.45 and a two-hundred day simple moving average of $18.83. The stock has a market capitalization of $1.44 billion, a PE ratio of -39.10 and a beta of 2.14.
In other Denali Therapeutics news, CEO Ryan J. Watts sold 8,581 shares of Denali Therapeutics stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $18.05, for a total transaction of $154,887.05. Following the completion of the sale, the chief executive officer now directly owns 12,505 shares of the company’s stock, valued at approximately $225,715.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Alexander O. Schuth sold 7,500 shares of Denali Therapeutics stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.16, for a total value of $136,200.00. 21.20% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Baillie Gifford & Co. lifted its holdings in Denali Therapeutics by 18.3% during the 2nd quarter. Baillie Gifford & Co. now owns 7,407,229 shares of the company’s stock worth $153,773,000 after buying an additional 1,145,003 shares during the last quarter. BlackRock Inc. lifted its holdings in Denali Therapeutics by 13.3% during the 2nd quarter. BlackRock Inc. now owns 5,154,097 shares of the company’s stock worth $106,999,000 after buying an additional 604,766 shares during the last quarter. Wasatch Advisors Inc. lifted its holdings in Denali Therapeutics by 21.3% during the 2nd quarter. Wasatch Advisors Inc. now owns 996,147 shares of the company’s stock worth $20,680,000 after buying an additional 175,243 shares during the last quarter. Pictet Asset Management Ltd. purchased a new stake in Denali Therapeutics during the 2nd quarter worth about $15,349,000. Finally, Northern Trust Corp lifted its holdings in Denali Therapeutics by 1.0% during the 2nd quarter. Northern Trust Corp now owns 620,050 shares of the company’s stock worth $12,873,000 after buying an additional 6,063 shares during the last quarter. 74.87% of the stock is owned by institutional investors.
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.